Astec Lifesciences Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter
- September 9, 2026
- Posted by: Harsh Piplani
- Category: Results
Astec Lifesciences share price Rs 750.25 on 9 September 2026, up 13.19%. Q2 FY27 results date not confirmed. Q1 FY27 net profit Rs 19.00 crore loss. Q2 FY26 base a loss of Rs 24.00 crore.
Quick Answer
The Astec Lifesciences Q2 results date for FY27 is not confirmed, and Astec Lifesciences Ltd. had not filed a board meeting intimation with the NSE or BSE as of 9 September 2026. Indian listing rules require the September 2026 quarter results to be published within 45 days of the quarter end, an outer deadline of 14 November 2026. The quarter will be measured against a September 2025 base of Rs 74.00 crore in revenue and a loss of Rs 24.00 crore. This preview uses reported actuals only and carries no estimated revenue or profit figure for the coming quarter.
The Astec Lifesciences Q2 results FY27 announcement is the next scheduled earnings event for Astec Lifesciences Ltd., a contract and own-brand manufacturer of agrochemical active ingredients, mainly fungicides, and formulations sold in India and exported to around two dozen countries as part of the Godrej Agrovet group. The stock traded at Rs 750.25 on the NSE on 9 September 2026, up 13.19% from the previous close of Rs 662.80, about 20.3% below its 52-week high of Rs 941.75 and 46.1% above its 52-week low of Rs 513.40.
What makes the Astec Lifesciences Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 74.00 crore of revenue and a loss of Rs 24.00 crore, while the most recent quarter on record, Q1 FY27, produced Rs 84.00 crore and a loss of Rs 19.00 crore. Everything below is built from those reported figures rather than from any forecast.
Click Here – Get Free Investment Predictions
When Is the Astec Lifesciences Q2 Results FY27 Date?
The Astec Lifesciences Q2 results date for FY27 is not confirmed. As of 9 September 2026, Astec Lifesciences Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.
What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Astec Lifesciences Q2 results date becomes public through that filing rather than through any advance announcement.
The Astec Lifesciences Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Astec Lifesciences.
Astec Lifesciences Q2 Results Expectations: What the Market Is Actually Tracking
No verified analyst estimate for the Astec Lifesciences Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Astec Lifesciences. The Astec Lifesciences Q2 results watchlist below is built from what the company has actually reported and disclosed.
The first is that all five quarters recorded a net loss, so this is a loss comparison. The September 2025 base was a loss of Rs 24 crore on revenue of Rs 74 crore with a negative 9% operating margin.
The second is the fixed cost base. Interest of Rs 7 crore to Rs 8 crore and depreciation of Rs 10 crore to Rs 12 crore a quarter together exceed any operating profit the company has generated, which is why even the positive-margin quarters still lost money.
The third is that operating margin was negative in three of the five quarters, including Q1 FY27 at negative 0.8%. The losses narrowed into March 2026 and then widened again, so the trend has not been continuous.
Check Astec Lifesciences Ltd. Live Fundamentals on the Univest Screener
Astec Lifesciences Q2 Results Preview: The Q1 FY27 Actuals It Builds On
Astec Lifesciences Ltd. reported revenue of Rs 84.00 crore in Q1 FY27, down 7.69% from Rs 91.00 crore in Q1 FY26, and a loss of Rs 19.00 crore at the net level, a narrower loss than the Rs 33.00 crore loss of Q1 FY26. These are reported actuals, not estimates.
Sequentially, revenue was down 47.17% over the March 2026 quarter figure of Rs 159.00 crore, and net profit was a wider loss than the Rs 8.00 crore loss of Q4 FY26. Operating margin stood at negative 0.8% in Q1 FY27 against negative 9% in the September 2025 quarter, which is the comparison the Astec Lifesciences Q2 results print will be read against.
Q2 FY26 Base: The Comparison Astec Lifesciences Q2 Results FY27 Must Beat
Astec Lifesciences Ltd. reported revenue of Rs 74.00 crore and a loss of Rs 24.00 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Astec Lifesciences Q2 results preview.
Because the base quarter itself was loss-making, a year-on-year percentage comparison of profit is not meaningful for Astec Lifesciences. The more useful test in the Astec Lifesciences Q2 results print is whether the company reports a profit at all, and how the income line of Rs 74.00 crore compares with the Rs 84.00 crore of the June 2026 quarter.
Astec Lifesciences Quarterly Results Trend Over the Last Four Quarters
| Quarter | Revenue (Rs Cr) | Net Profit (Rs Cr) |
|---|---|---|
| Q2 FY26 (Sep 2025) | 74.00 | (24.00) |
| Q3 FY26 (Dec 2025) | 125.00 | (16.00) |
| Q4 FY26 (Mar 2026) | 159.00 | (8.00) |
| Q1 FY27 (Jun 2026) | 84.00 | (19.00) |
Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company’s exchange filings, and they are the only basis this Astec Lifesciences Q2 results preview uses.
Revenue across those four quarters ranged from Rs 74.00 crore to Rs 159.00 crore, and net profit from Rs 24.00 crore loss to Rs 8.00 crore loss. That spread is the honest context for the Astec Lifesciences Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.
Key Factors That Could Shape Astec Lifesciences Q2 Results FY27
The Astec Lifesciences Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Astec Lifesciences has already reported.
Agrochemical Prices and Chinese Supply
Fungicide active ingredient prices have been under pressure from oversupply, and realisation moves faster than the cost base can be cut. That spread is what turned a previously profitable business loss-making.
No Tax Credit Against the Losses
The tax rate was zero or negative in all five quarters, meaning no deferred tax asset is being recognised against the accumulated losses. Reported loss therefore equals pre-tax loss in every quarter.
Borrowings Exceed Reserves
Borrowings of about Rs 449 crore sit against reserves of Rs 368 crore, so the interest charge falls on a business already loss-making. Return on equity is negative 25.20% and no earnings multiple can be quoted.
Astec Lifesciences Q2 Results FY27: Share Price and Valuation Going Into the Print
Astec Lifesciences share price today is Rs 750.25 on the NSE, up Rs 87.45 or 13.19% from the previous close of Rs 662.80 on 9 September 2026, ahead of the Astec Lifesciences Q2 results announcement.
| Metric | Value (9 September 2026) |
|---|---|
| NSE Symbol | ASTEC |
| Current Market Price | Rs 750.25 |
| 52-Week High | Rs 941.75 |
| 52-Week Low | Rs 513.40 |
| Market Capitalisation | Rs 1,671 crore |
| PE Ratio | Not meaningful |
| PB Ratio | 4.29 |
| EPS (TTM) | Not meaningful |
| Book Value per Share | Rs 175.00 |
| Debt to Equity | 1.15 |
| Return on Equity | -25.20% |
| 50-Day Moving Average | Rs 635.41 |
| 200-Day Moving Average | Rs 674.15 |
| RSI (14) | 76.45 |
The stock trades above both its 50-day average of Rs 635.41 and its 200-day average of Rs 674.15, with a 14-day RSI of 76.45. None of this is a view on where the shares go once the Astec Lifesciences Q2 results are announced, and no price target is offered here.
Download the Univest iOS App or Univest Android App to track Astec Lifesciences Ltd. live price and quarterly earnings updates.
What Investors Should Watch When Astec Lifesciences Q2 Results Are Announced
Four lines carry most of the information in a company of this size, and reading them in order keeps the Astec Lifesciences Q2 results print in proportion.
- Revenue against the Rs 74.00 crore reported in the September 2025 base quarter
- Net profit against a loss of Rs 24.00 crore in that same quarter
- Operating margin against negative 0.8% in Q1 FY27
- Any exceptional item, provision or one-off gain disclosed alongside the numbers
A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Astec Lifesciences Q2 results announcement should be read together with the notes to the results rather than the headline alone.
Conclusion on Astec Lifesciences Q2 Results FY27
The Astec Lifesciences Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Astec Lifesciences Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.
On that basis the Astec Lifesciences Q2 results FY27 print faces a base of Rs 74.00 crore in revenue and a loss of Rs 24.00 crore, with the most recent quarter having delivered Rs 84.00 crore and a loss of Rs 19.00 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Astec Lifesciences, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Astec Lifesciences Q2 Results FY27
What is the Astec Lifesciences Q2 results date for FY27?
Ans. The Astec Lifesciences Q2 results date for FY27 is not confirmed. Astec Lifesciences Ltd. had not filed a board meeting intimation with the NSE or BSE as of 9 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.
What quarter do the Astec Lifesciences Q2 results 2026 cover?
Ans. The Astec Lifesciences Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Astec Lifesciences Ltd. reports revenue, operating profit and net profit for that period, and the Astec Lifesciences Q2 results filing also carries the notes to the accounts.
What were the Astec Lifesciences Q1 FY27 results?
Ans. Astec Lifesciences Ltd. reported revenue of Rs 84.00 crore in Q1 FY27 and a loss of Rs 19.00 crore at the net level. Revenue was down 7.69% versus Q1 FY26 and net profit was a narrower loss than the Rs 33.00 crore loss of Q1 FY26.
What were Astec Lifesciences Q2 FY26 results in the September 2025 quarter?
Ans. Astec Lifesciences Ltd. reported revenue of Rs 74.00 crore and a loss of Rs 24.00 crore in Q2 FY26. Operating margin was negative 9%. Those figures form the base for the Astec Lifesciences Q2 results FY27 comparison.
What are the main Astec Lifesciences Q2 results expectations this quarter?
Ans. No verified analyst estimate is publicly available. The Astec Lifesciences Q2 results expectations centre on revenue against the Rs 74.00 crore base, net profit against a loss of Rs 24.00 crore, operating margin against negative 0.8% in Q1 FY27, and any exceptional item disclosed with the numbers.
What is Astec Lifesciences share price today ahead of the Q2 earnings?
Ans. Astec Lifesciences share price is Rs 750.25 on the NSE as of 9 September 2026, up 13.19% from Rs 662.80. The stock is about 20.3% below its 52-week high of Rs 941.75 and 46.1% above its 52-week low of Rs 513.40, at a market capitalisation of Rs 1,671 crore.
Is Astec Lifesciences a good stock to buy before the Q2 results?
Ans. This article does not offer a buy, sell or hold recommendation on Astec Lifesciences Ltd.. The stock trades at a price-to-book ratio of 4.29 with a return on equity of -25.20%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.
